17 research outputs found

    Patients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor- β1, and vascular endothelial growth factor

    Get PDF
    Introduction: Encapsulating peritoneal sclerosis (EPS) is a devastating complication of peritoneal dialysis (PD). The pathogenesis is not exactly known and no preventive strategy or targeted medical therapy is available. CCN2 has both profibrotic and pro-angiogenic actions and appears an attractive target. Therefore, we studied peritoneal expression of CCN2, as well as TGFb1 and VEGF, in different stages of peritoneal fibrosis.Materials and methods: Sixteen PD patients were investigated and compared to 12 hemodialysis patients and four preemptively transplanted patients. Furthermore, expression was investigated in 12 EPS patients in comparison with 13 PD and 12 non-PD patients without EPS. Peritoneal tissue was taken during kidney transplantation procedure or during EPS surgery. In a subset of patients, CCN2 protein levels in peritoneal effluent and plasma were determined. Samples were examined by qPCR, histology, immunohistochemistry, and ELISA.Results: Peritoneal CCN2 expression was 5-fold higher in PD patients compared to pre-emptively transplanted patients (P< 0.05), but did not differ from hemodialysis patients. Peritoneal expression of TGFβ1 and VEGF were not different between the three groups; neither was peritoneal thickness. Peritoneum of EPS patients exhibited increased expression of CCN2 (35- fold, P<0.001), TGFβ1 (24-fold, P< 0.05), and VEGF (77-fold, P<0.001) compared to PD patients without EPS. In EPS patients, CCN2 protein was mainly localized in peritoneal endothelial cells and fibroblasts. CCN2 protein levels were significantly higher in peritoneal effluent of EPS patients compared to levels in dialysate of PD patients (12.0±4.5 vs. 0.91±0.92 ng/ml, P<0.01), while plasma CCN2 levels were not increased.Conclusions: Peritoneal expression of CCN2, TGFβ1, and VEGF are significantly increased in EPS patients. In early stages of peritoneal fibrosis, only CCN2 expression is slightly increased. Peritoneal CCN2 overexpression in EPS patients is a locally driven response. The potential of CCN2 as biomarker and target for CCN2-inhibiting agents to prevent or treat EPS warrants further study

    Presença de "Linha Morgan" como indicador de displasia coxofemoral em cães da raça Pastor-Alemão Presence of Morgan-Line as an indicator of canine hip dysplasia in German Shepherd dogs

    No full text
    <abstract language="eng">The aim of this study was to determine the relationship between the presence of Morgan line and hip dysplasia. From June, 1986 to October, 1993, 190 X-ray plates of German Shepherd dogs, from both sexes were collected and analyzed. The results showed that out of the 190 dogs evaluated, 136 (71.6%) had hip dysplasia, 43 (22.6%) presented Morgan line and 41 (21.5%) showed both of them. Just two (1.1%) dogs presented Morgan line without hip dysplasia. No statistically significant difference was found between males (21.8%) and females (23.3%). From this study it can be concluded that the presence of the Morgan line can be considered indicative to hip dysplasia diagnosis, even though the absence of the line does not exclude the possibility of hip dysplasia
    corecore